NAD+ repletion with nicotinamide (NAM) or the PARP inhibitor PJ34 prevented both NAD+ depletion and the production of thymus atrophy and hepatosteatosis by TCDD, supporting a role for NAD+ loss in different TCDD toxicities in vivo. The gene discussed is PARP1; the disease is thymus atrophy.